成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 82571-53-7 Chemical Structure| 82571-53-7

Structure of Ozagrel
CAS No.: 82571-53-7

Chemical Structure| 82571-53-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 82571-53-7

,{[proInfo.pro_purity]}

Ozagrel is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.

Synonyms: OKY-046

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ozagrel

CAS No. :82571-53-7
Formula : C13H12N2O2
M.W : 228.25
SMILES Code : O=C(O)/C=C/C1=CC=C(CN2C=CN=C2)C=C1
Synonyms :
OKY-046
MDL No. :MFCD00868231
InChI Key :SHZKQBHERIJWAO-AATRIKPKSA-N
Pubchem ID :5282440

Safety of Ozagrel

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Rabbit pulmonary artery endothelial cells 10 μM 40 min Inhibited TXA2 synthase, reduced TXB2 release, and attenuated stretch-induced contraction PMC1564919
HEK293 cells 10 μM 20 s To investigate the effect of Ozagrel on 12-HHT and TxB2 production. Results showed that Ozagrel partially inhibited 12-HHT production but completely inhibited TxB2 production. PMC3793602

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Guinea-pigs Capsaicin-induced cough model Oral 10, 30, and 100 mg/kg Administered 1 hour before capsaicin provocation To evaluate the inhibitory effect of Ozagrel on capsaicin-induced cough, results showed Ozagrel dose-dependently reduced cough counts (ED50 value, 26.3 mg/kg). PMC1572314
Mongolian gerbils Transient bilateral carotid artery occlusion model Intraperitoneal injection 30 mg/kg Single dose To evaluate the neuroprotective effects of Ozagrel against ischemia-induced neuronal loss. Results showed that Ozagrel did not significantly protect CA1 neurons in the hippocampus from ischemia-induced loss. PMC1909837
Sprague Dawley rats Cortical spreading depression (CSD) model Topical epidural administration 1 mM Single dose, observed for 50 minutes To evaluate the effect of Ozagrel on CSD-evoked cerebral oligemia. Results showed that Ozagrel partially inhibited the early decrease in CBF ("dip" phase) but had no significant effect on the later persistent oligemia. PMC5363480
ICR mice Adenomyosis mouse model Intraperitoneal injection 12.5 μg/g, 25 μg/g Once daily for 3 weeks To evaluate the effect of antiplatelet therapy in a mouse model of adenomyosis. Results showed that Ozagrel dose-dependently suppressed myometrial infiltration, improved generalized hyperalgesia, reduced uterine contractility, and lowered plasma corticosterone levels, improved the expression of some proteins known to be involved in adenomyosis and slowed down the process of fibrogenesis. PMC5057470
Stroke-prone spontaneously hypertensive rats (SHRSP) Animal model of human essential hypertension Drinking water 3.5 mM, in drinking water 5 weeks Ozagrel significantly suppressed TXAS mRNA expression and significantly improved histological injury PMC8075916

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.38mL

0.88mL

0.44mL

21.91mL

4.38mL

2.19mL

43.81mL

8.76mL

4.38mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories